With Trump's tariffs looming, is this really the appropriate time to load up on pharma stocks? And where does Cipla stand in ...

Indian firms have been focusing on complex generics for some time now, which insulates them partially from pricing pressures ...

The hope is the therapy can effectively target cancerous cells at relatively small doses while minimizing side effects.

A new study has identified a novel strategy for treating acute myelogenous leukemia (AML), an aggressive blood cancer for which the median survival time following diagnosis remains just 8.5 months.

The FDA has approved Opdivo (nivolumab) in combination with Yervoy (ipilimumab) for unresectable or metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.